PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34826777-4	2022	We have previously shown that targeting sphingolipid metabolism with the sphingosine kinase 2 (SK2) inhibitor K145 in combination with bortezomib induces synergistic death of bortezomib-naive myeloma.	K145	110-114	sphingosine kinase 2	Homo sapiens	73-93
34826777-4	2022	We have previously shown that targeting sphingolipid metabolism with the sphingosine kinase 2 (SK2) inhibitor K145 in combination with bortezomib induces synergistic death of bortezomib-naive myeloma.	K145	110-114	sphingosine kinase 2	Homo sapiens	95-98
32124438-9	2020	Additionally, the use of ABC294640 or K145, both SPHK2-specific inhibitors, decreased viability of LGL leukaemia cell lines.	K145	38-42	sphingosine kinase 2	Homo sapiens	49-54
28911865-0	2017	3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway.	K145	79-83	thymoma viral proto-oncogene 1	Mus musculus	165-168
28911865-0	2017	3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) ameliorated dexamethasone induced hepatic gluconeogenesis through activation of Akt/FoxO1 pathway.	K145	79-83	forkhead box O1	Mus musculus	169-174
28911865-1	2017	3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) is identified as a selective SphK2 inhibitor.	K145	79-83	sphingosine kinase 2	Mus musculus	114-119
28911865-5	2017	Besides, both in vivo and in votro studies suggested that K145 stimulated insulin dependent Akt phosphorylation and subsequently activates FoxO1 phosphorylation therefore inhibited gluconeogenetic genes expression including PEPCK and G6pase.	K145	58-62	thymoma viral proto-oncogene 1	Mus musculus	92-95
28911865-5	2017	Besides, both in vivo and in votro studies suggested that K145 stimulated insulin dependent Akt phosphorylation and subsequently activates FoxO1 phosphorylation therefore inhibited gluconeogenetic genes expression including PEPCK and G6pase.	K145	58-62	forkhead box O1	Mus musculus	139-144
28911865-5	2017	Besides, both in vivo and in votro studies suggested that K145 stimulated insulin dependent Akt phosphorylation and subsequently activates FoxO1 phosphorylation therefore inhibited gluconeogenetic genes expression including PEPCK and G6pase.	K145	58-62	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	224-229
28911865-5	2017	Besides, both in vivo and in votro studies suggested that K145 stimulated insulin dependent Akt phosphorylation and subsequently activates FoxO1 phosphorylation therefore inhibited gluconeogenetic genes expression including PEPCK and G6pase.	K145	58-62	glucose-6-phosphatase, catalytic	Mus musculus	234-240
23437140-0	2013	Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.	K145	110-114	sphingosine kinase 2	Homo sapiens	131-151
23437140-2	2013	Biochemical assay results indicate that K145 is a selective SphK2 inhibitor.	K145	40-44	sphingosine kinase 2	Homo sapiens	60-65
23437140-5	2013	K145 also exhibited inhibitory effects on the growth of U937 cells as well as apoptotic effects in U937 cells, and that these effects may be through the inhibition of down-stream ERK and Akt signaling pathways.	K145	0-4	mitogen-activated protein kinase 1	Homo sapiens	179-182
23437140-8	2013	Collectively, these results strongly encourage further optimization of K145 as a novel lead compound for development of more potent and selective SphK2 inhibitors.	K145	71-75	sphingosine kinase 2	Homo sapiens	146-151
19210780-6	2009	Some critical interactions in the binding site such as the salt bridge formed between K145/D200 in the neurotoxin-nAChR complex is further stabilized during the MD simulation, while it is obviously more labile in the apo form.	K145	86-90	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	114-119
34607257-6	2021	Consistent to in vivo study, in vitro study also confirmed the role of K145 in decreasing lipid accumulation in human HL7702 cells, while inhibiting FAS, ACC1 and SREBP1c mRNA expression.	K145	71-75	BCL2 related protein A1	Homo sapiens	154-158
34607257-6	2021	Consistent to in vivo study, in vitro study also confirmed the role of K145 in decreasing lipid accumulation in human HL7702 cells, while inhibiting FAS, ACC1 and SREBP1c mRNA expression.	K145	71-75	sterol regulatory element binding transcription factor 1	Homo sapiens	163-170
26621495-13	2016	Our results showed that HPC significantly increased SphK2 expression in primary cardiomyocytes under normal or H/R condition and protected against H/R-induced cell apoptosis, whereas SphK2 inhibitor K145 abolished the cardioprotective effect of HPC.	K145	199-203	sphingosine kinase 2	Rattus norvegicus	183-188
20726599-5	2010	However, introduction of the charged HA residues K145 and E227 in the 2009 HA binding pocket was found to increase the HA-hHAR binding efficiency in comparison to the three previously recognized H1N1 strains.	K145	49-53	lymphatic vessel endothelial hyaluronan receptor 1	Homo sapiens	122-126